Capricor Therapeutics (CAPR) Misses Q1 EPS by 2c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/8/2026

1. SPCX
2. LEVI
3. SBUX
4. NVDA
5. GOOGL
6. APLD
7. ORCL
8. USO
9. STZ
10. AAPL

Go back to Capricor Therapeutics (CAPR) Misses Q1 EPS by 2c

Capricor Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update

May 10, 2018 4:00 PM EDT

HOPE-2 Clinical Trial is Currently Enrolling Patients

Conference Call and Webcast Today at 4:30 p.m. ET

LOS ANGELES, May 10, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare... More